Category: Latest News
-
Redwire Shares Drop Sharply Following Pricing of Enlarged Public Offering
Redwire Corp (NYSE:RDW) saw its stock decline 17.5% after the aerospace and defense tech firm announced pricing for its upsized common stock offering at $16.75 per share. The company plans to issue 15.5 million shares, aiming to raise roughly $260 million in gross proceeds. Additionally, underwriters have been granted a 30-day option to buy up…
-
Fold Holdings Shares Rise After Securing $250 Million Equity Facility for Bitcoin Expansion
Fold Holdings, Inc. (NASDAQ:FLD) saw its stock spike as much as 21% before settling up 4%, after announcing a major equity facility aimed at bolstering its bitcoin reserves. The company, which positions itself as the first publicly listed financial services provider focused on bitcoin, has arranged a $250 million equity purchase facility to support its…
-
Mineralys Therapeutics Shares Climb on Strong Results from Kidney Disease Trial
Shares of Mineralys Therapeutics Inc. (NASDAQ:MLYS) jumped 7.9% following the release of promising topline data from the company’s Phase 2 Explore-CKD study evaluating lorundrostat in patients with chronic kidney disease (CKD) and hypertension. The trial reached its primary endpoint, demonstrating a notable 7.5 mmHg reduction in systolic blood pressure compared to placebo — a result…
-
Wiley Shares Pop 8% Following Q4 Earnings and Positive Outlook for FY2026
Shares of John Wiley & Sons, Inc. (NYSE: WLY) surged 8% in premarket trading on Tuesday after the academic publisher delivered stronger-than-expected fourth quarter earnings and offered encouraging guidance for the upcoming fiscal year. For the quarter ending April 30, Wiley posted adjusted earnings of $1.37 per share, beating the consensus estimate of $1.31. Quarterly…
-
Jabil Stock Climbs on Strong Q3 Results and Upbeat Forecast
Shares of Jabil Inc. (NYSE:JBL) gained 5.05% after the electronics manufacturing services provider posted third-quarter results that beat Wall Street expectations and boosted its full-year guidance. For the fiscal quarter ending May 31, Jabil reported adjusted earnings of $2.55 per share, ahead of analysts’ consensus of $2.29. Revenue rose to $7.8 billion, exceeding the $7.03…
-
Surgery Partners Shares Slide After Ending Buyout Talks with Bain Capital
Shares of Surgery Partners, Inc. (NASDAQ:SGRY) dropped 12% following the announcement that the company has wrapped up acquisition discussions with Bain Capital without reaching a deal. A Special Committee composed of independent board members reviewed Bain Capital’s non-binding offer to acquire the remaining shares it does not already own. After evaluation, the committee concluded that…
-
Immuneering Shares Climb on Promising Pancreatic Cancer Trial Results
Shares of Immuneering Corporation (NASDAQ:IMRX) rose 7% on Monday following the release of encouraging interim results from a Phase 2a clinical trial evaluating its experimental cancer therapy, atebimetinib, in combination with modified gemcitabine/nab-paclitaxel (mGnP), as a first-line treatment for pancreatic cancer. The clinical-stage biotech reported that, six months into the study, 94% of patients were…
-
Dyne Therapeutics Shares Slide After FDA Meeting Spurs Revised Accelerated Approval Plan for DM1 Drug
Shares of Dyne Therapeutics (NASDAQ:DYN) plunged 23% after the biotech firm announced changes to its regulatory strategy for DYNE-101, a treatment for myotonic dystrophy type 1 (DM1), following a recent Type C meeting with the U.S. Food and Drug Administration. Although the FDA granted Breakthrough Therapy Designation to DYNE-101—highlighting its potential to address serious unmet…
-
PureCycle Technologies Shares Pop After Securing $300 Million to Fuel Global Expansion
PureCycle Technologies (NASDAQ:PCT) saw its stock soar 12% after unveiling a major $300 million capital raise, signaling renewed investor confidence in the company’s long-term strategy to revolutionize plastic recycling and scale up its production capabilities. The funding, which combines contributions from both existing and new investors—including Duquesne Family Office LLC, Wasserstein Debt Opportunities, Samlyn Capital,…
-
Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results
Shares of Ventyx Biosciences (NASDAQ:VTYX) traded flat on Tuesday, even after the company released promising top-line results from a Phase 2a trial evaluating its investigational drug VTX3232 in patients with early-stage Parkinson’s disease. The biotech firm announced that the study successfully met its primary goal of establishing the drug’s safety and tolerability. Importantly, no treatment-emergent…